deucravacitinib Archives -

Bristol-Myers Squibb’s deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in

BMS scores first approval for psoriasis therapy Sotyktu

https://pharmaphorum.com/news/bms-scores-first-approval-for-psoriasis-therapy-sotyktu/

Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for

BMS adds to IBD pipeline with $1.9bn GentiBio deal

https://pharmaphorum.com/news/bms-adds-to-ibd-pipeline-with-1-9bn-gentibio-deal/

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it

Amgen builds Otezla’s psoriasis label as rival BMS looms large

https://pharmaphorum.com/news/amgen-builds-otezlas-psoriasis-label-as-rival-bms-looms-large/

The FDA has kicked off its review of Bristol-Myers Squibb’s psoriasis therapy deucravacitinib, setting an action date of

FDA sets Sept review date for BMS’ psoriasis drug deucravacitinib

https://pharmaphorum.com/news/fda-sets-sept-review-date-for-bms-psoriasis-drug-deucravacitinib/

Bristol-Myers Squibb’s hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD)

Failed IBD trial dents confidence in BMS’ deucravacitinib

https://pharmaphorum.com/news/failed-ibd-trial-dents-confidence-in-bms-deucravacitinib/

Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in

BMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rival

https://pharmaphorum.com/news/bms-deucravacitinib-psoriasis-pill-could-launch-next-year-after-outperforming-amgens-rival/

deucravacitinib